AZD2516
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 02, 2012
Safety evaluation of the mGluR5 antagonists AZD9272, AZD2066 AND AZD2516 in healthy volunteers and patients with neuropathic pain or major depressive disorder
(WCP 2012)
- Presentation time: Tuesday, August 28; 9:45 am; P1, N=116; In healthy volunteers the CNS-related AEs increased in frequency with increasing dose and were found to be subject to tolerance development in the AZD2066 multiple ascending dose (MAD) study; AEs were more common among those receiving active drug compared to placebo
P1 data • Pain
1 to 1
Of
1
Go to page
1